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Aims Treatment of tricuspid regurgitation (TR) is common after surgery for mitral and/or aortic valves. The prognostic
role of moderate to severe TR in patients undergoing mitraclip or transcatheter aortic valve implantation (TAVI) is
not well-defined. Thus, the aim of this article is to perform a systematic review and meta-analysis of articles valuing




Articles were searched in Pubmed, Cochrane Library, Google Scholar and Biomed Central in September 2016.
Inclusion criteria: observational or randomized clinical trials with data on the prognostic role of TR in patients
undergoing mitraclip or TAVI. Primary outcome was all-cause mortality expressed as hazard ratio (HR). Six articles
fulfilled inclusion criteria, three were on mitraclip and three on TAVI. A total of 2329 patients were analysed
(mean age was 78.38 (3.09), 63% male): 1328 treated with TAVI and 1001 with mitraclip. The HR for all-cause
mortality of moderate to severe TR was 2.0 (95% CI 1.57–2.55, I2 = 0%). Data were confirmed also after subgroup
analysis for mitraclip vs. TAVI. None of the factor considered in meta-regression analyses was affecting the primary
outcome.
...................................................................................................................................................................................................
Conclusions The current meta-analysis suggests that the presence of moderate to severe TR in patients undergoing mitraclip or
TAVI might be a major determinant of all-cause mortality. New studies are needed to confirm it and to plan pos-
sible intervention in order to reduce its impact.
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Introduction
Left heart valve disease is the most common cause of tricuspid regur-
gitation (TR).1 The prevalence of TR in patients undergoing left heart
valve surgery is ranging between 25 and 30%,2 and the loss of coapta-
tion due to annular or right ventricle dilatation the most usual cause
of TR.3 A recent meta-analysis on 2488 patients showed that the ab-
sence of treatment on tricuspid valve during mitral valve operations
is related to a higher risk of developing moderate to severe TR, even
when the valve defect is mild to moderate.4 For this reason, current
guidelines suggest the treatment of tricuspid valve in case of (i) severe
primary or secondary TR (Class I LoE C); (ii) moderate primary TR
(Class II LoE C); (iii) right annular dilatation (Class II LoE C).5 In the
last 10 years, the approach to the treatment of left heart valve disease
has changed, and for high risk patients, the percutaneous approach is
substituting the more conventional surgery.6–7 The selection criteria
for both patients treated with transcatheter aortic valve implantation
(TAVI) or with mitraclip do not take into account the presence of
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moderate to severe TR,6–7 despite the suggestion of an increased risk
of mortality in patients with moderate to severe TR.8–14 Considering
these data, we have performed a systematic review and meta-analysis
on all the available evidences in the literature regarding the predictive
role TR on all-cause mortality or on cardiovascular death for patients
undergoing TAVI or mitraclip.
Methods
Search strategy
We performed a systematic review and meta-analysis following preferred
reporting items for systematic reviews and meta-analyses (PRISMA)
amendment to the quality of reporting of meta-analyses (QUOROM)
statement.15–18 The search strategy was elaborated in September 2016.
The terms searched were (((mitraclip) OR ((transcatheter) OR (percu-
taneous) AND (mitral valve repair)) OR ((TAVI) OR (transcatheter aor-
tic valve implantation))) AND ((outcome) OR (mortality) OR (cardiac
death) OR (hospitalization) OR (heart failure) OR (reintervention)). The
databases analysed were Google Scholar, Pubmed, Biomed Central, and
Cochrane library. Only articles published in English and in peer-reviewed
journal were selected. Two independent reviewers analysed the records
and decided the ones deserving a full-text analysis.
Selection criteria
The inclusion criteria for the studies were: (i) observational or random-
ized clinical trials (RCTs) in patients treated with mitraclip or TAVI;
(ii) evaluation of the TR degree; (iii) data on the predictive role of TR on
all-cause mortality or cardiovascular mortality expressed as adjusted
odds ratio (OR) or hazard ratio (HR); (iv) inclusion of at least 50 patients.
Exclusion criteria were: (i) duplicate reports; (ii) duplicate of the sample
size; (iii) case reports/series. The same reviewers (RP, SR) independently
analysed references of all the evaluated articles for avoiding the eventual
exclusion of additional studies. All the authors agreed on the final number
of studies included.
Data abstraction, endpoints, and
subgroup analyses
The reviewers completed a database with data regarding: the journal,
year of publication, the hospital centre, population characteristics, echo-
cardiographic data (degree of TR, ejection fraction (EF), systolic pulmon-
ary arterial pressure (sPAP), valve implanted, variables analysed at
multivariate analysis). The primary endpoint of the analysis was the HR of
moderate to severe TR in patients undergoing TAVI or mitraclip proced-
ures. A subgroup analysis according the kind of procedure done
(mitraclip vs. TAVI) and the length of the follow-up (<_ 1 year vs. >1 year)
was also performed. The secondary endpoint was cardiovascular mortal-
ity. The definition of the severity of TR for analysis differed between art-
icles: Ohno et al.,9 Hutter et al.,12 and Barbanti et al.13 and considered
moderate/severe TR vs. mild/none; Giannini considered a TR grade > 2;10
Puls et al.8 considered severe TR; Lindman considered mild vs. moderate
vs. severe and we decided to use the HR of all-cause mortality for severe
TR.11
Internal validity and quality appraisal
Two unblinded reviewers evaluated the quality of included studies using
pre-specified electronic forms that were piloted over the first three cases
and using a modified version of the Newcastle-Ottawa Scale for cohort
studies (Table 2).19 The divergences were resolved by consensus. No
studies were excluded on the basis of this analysis.
Data analysis and synthesis
Continuous variables were reported as mean [±standard deviation (SD)]
or median [interquartile range (IQR)]. To convert median (IQR) to mean
(SD) we used formula accepted in the literature.20 Categorical variables
were expressed as number and percentage (%). Continuous variables
were reported as mean (±SD) or median (IQR). The endpoints were ex-
pressed as HR. Point estimates and standard errors were calculated and
combined by the generic inverse variance method,21 computing risk esti-
mates with 95% confidence intervals (CIs) according to logarithmic trans-
formation of the hazard measures. Considering the high likelihood of
between-study variance, we used a random effect model. Statistical het-
erogeneity was assessed using the Cochran’s Q test and I2 statistic with a
value of I2 of 0–25% considered insignificant heterogeneity, 26–50% low
heterogeneity, 51–75% moderate heterogeneity, and >75% high hetero-
geneity.22 To test the difference between sub-group analyses the v2 test
has been used. Finally, random effect meta-regression analysis was per-
formed to assess the effect of some potential confounding factors (sex,
previous myocardial infarction, diabetes, hypertension, and severe kidney
disease) on results. Publication bias was appraised by graphical valuation
of funnel plots and through Begg and Mazumdar rank correlation, Egger’s
regression intercept, and Duval and Tweedie trim and fill.23 Prometa soft-
ware 3 (Internovi, Cesena, Itay) and RevMan 5 (The Cochrane
Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark)
were the software used for statistical analysis.
Results
Search strategy
A total of 815 records were analysed: 687 about mitraclip and 128
about TAVI (Figure 1). After a first evaluation of titles and abstracts 86
records were screened and 77 of these were excluded because they
failed to report on TR. Nine studies were analysed as full-article
(Figure 1). Three articles were excluded: one was a review, one was
not reporting data about TR and all-cause mortality and one14 (Figure
1) was a possible sample duplicate of the population of Puls et al.8 Six
studies were included in qualitative and quantitative analysis.8–14 Of
these only the study of Lindman et al.11 was a RCT, all the others
were observational studies.8–10,12,13
Population characteristics
A total of 2329 patients were analysed: 1328 treated with TAVI and
1001 with mitraclip. The mean age was 78.38 (3.09), 63% of patients
were male. Hypertension was present in 39% of the population, dia-
betes in 25%, a previous myocardial infarction affected the 16% of the
patients (Table 1) and atrial fibrillation 37% of the population. Mean
EF pre procedure was 41% (14%); mean pre procedure sPAP was
50(7) mmHg and mean EuroSCORE was 20(06).
Primary outcome and secondary
outcomes
The HR for all-cause mortality of moderate to severe TR in patients
undergoing TAVI or mitraclip was 2.0 (95% CI 1.57–2.55) (Figure 2).
The HR just for patients undergoing TAVI was 2.10 (95% CI 1.52–
2.91) and for those receiving mitraclip was 1.87 (95% CI 1.30–2.71)
(Figure 2). Subgroup analysis according the length of the follow-up dis-
closed the absence of statistical significance (HR 2, P < 0.00001 for
follow-up <_ 1 year versus HR 1.89, P = 0.04 for follow-up <1 year,





















..v2 = 0.03, P = 0.87) (Supplementary data online, eFigure S1). Of note,
data from Hutter et al. relates to the univariate analysis. After the ex-
clusion of the study of Hutter et al., the cumulative HR for all-cause
death did not change (HR 2.03; 95% CI 1.52–2.71) (Supplementary
data online, eFigure S2). The heterogeneity between study was insig-
nificant (I2 = 0%). None of the factor considered in meta-regression
analyses was affecting the primary outcome. The analyses disclosed
the absence of publication bias (P for Egger’s linear regression
test = 0.213, P for Begg and Mazumdar’s rank correlation test = 0.142;
0 trimmed studies) (Figure 3).
Finally, only the study of Giannini et al. reported the HR of TR > 2
for cardiovascular death, showing the absence of predictive value at
Figure 1 Outline of the search strategy.
....................................................................................................................................................................................................................
Table 1 Sample characteristics












Factors valued at multivariate analysis
Barbanti 2015 OBS P T 518 55 78 30 NA 38 38 2 PM, AF, mean trans-aortic gradient, renal failure.
Giannini 2015 OBS R M 169 78 68 33 64 26 40 3 age, logistic EuroSCORE, GFR < 30, AF,
LVEDD, LVEDV, LVESV, LVEF, LA area,
TAPSE, RV PVS TDI
Hutter 2013 OBS P T 268 38 NA NA 53 19 23* 1 only data available for univariate analysis
Lindman 2015 RCT T 542 75 51 15 25 6 30 1 age, sex, BMI, STS score, prior MI, prior CABG,
frailty, PM, atrial arrhythmia, aortic valve mean
gradient, LVEF, and MR
Ohno 2014 OBS P M 146 64 75 39 NA 51 38 1 chronic kidney disease and AF
Puls 2016 OBS P M 749 61 78 30 NA 62 44 1 age, sex, NYHA; anaemia, previous aortic valve
implantation, creatinine > 1.5, PAD,
LVEF < 30, procedural failure
OBS, observational; P, prospective; R, retrospective; HPT, hypertension; GFR, glomerular filtration rate; PM, pacemaker, AF, atrial fibrillation; LVEDD, left ventricle end diastolic
diameter; LVEDV, left ventricle end diastolic volume; LVESV, left ventricle end systolic volume; LA, left atrium; TAPSE, tricuspid annular plane systolic excursion; BMI, body
mass index; MI, myocardial infarction; CABG, coronary artery bypass graft; LVEF, left ventricle ejection fraction; MR, mitral regurgitation; PAD, peripheral artery disease;
NYHA, New York Heart Association; NA, not assessed; RCT, randomized clinical trials; T/M: TAVI or Mitraclip; RV PVS TDI: right ventricle pulse velocity systolic tissue doppler
imaging; STS: The Society of Toracic Surgeons; *, atrial arrhythmia.




































..the multivariate analysis (HR 1.33, 95% CI 0.29–6.10) for patients
undergoing mitraclip.
Discussion
At the state of the art, this is the first systematic review on the pre-
dictive role of TR on all-cause mortality in patients undergoing
mitraclip or TAVI procedure. The data are confirmed for both pro-
cedures and no-one of the factors valued at the meta-regression ana-
lysis affected the outcome. Interestingly, even if the studies were
conducted on patients with mixed diseases (mitral regurgitation vs.
aortic stenosis), the heterogeneity expressed as I2 was insignificant,
even more corroborating the data obtained. Unfortunately, it was
not possible to draw any conclusion on cardiovascular death since
only the study by Giannini et al.10 was focused on this outcome and
enrolled a small number of patients undergoing mitraclip. The popu-
lation analysed in our meta-analysis was a high risk one as showed by
the mean age, EF, PAPs, and EuroSCORE. Our results represent the
first step in the understanding of the relationship between TR and
outcome in patients undergoing percutaneous repair of left heart
valve disease. However, there are several questions still unsolved.
First of all, does TR play a primary role in determining the outcome
of these patients or is it just a marker of patients’ risk and complexity?
In this regard, current available data are scanty and conflicting. On
one side, the study of Barbanti et al.13 showed that, in patients treated
with TAVI, the risk for all-cause mortality was higher in those with
moderate to severe TR, only in case of EF > 40%. Authors suggested
that comorbidities are the real responsible of the adverse outcome
in the presence of severe TR, and that severe TR could be considered
as a surrogate marker of other concomitant risk factors. On the
other side, in patients treated with mitraclip, the presence of
Figure 2 Forest plot of the studies valuing the relation between the presence of moderate to severe TR and all-cause mortality in patients
undergoing mitraclip or TAVI procedure. Data are displayed as HR (95% CI).
....................................................................................................................................................................................................................
Table 2 New Castle Ottawa scale for quality assessment
References Score (max 6) Selection 1 Selection 2 Selection 3 Selection 4 Comparability 1 Outcome 1 Outcome 2 Outcome 3
Barbanti 4 a* NA a* a* NA d a* d
Giannini 5 a* NA a* a* NA b* a* d
Hutter 6 a* NA a* a* NA b* a* b*
Lindman 6 a* NA a* a* NA b* a* b*
Ohno 6 a* NA a* a* NA b* a* a*
Puls 6 a* NA a* a* NA b* a* b*
Only letter with * give points; NA, not assessed.
























































moderate to severe TR is predictive of a composite outcome of
death and hospital readmission for HF (P = 0.015) but only in patients
with EF < 35%.9 In this case, authors suggested that this particular
finding could be related to the high risk of these patients to develop
biventricular failure. Our meta-analysis did not give an answer to this
dilemma, even if it underlines once again the necessity to improve the
definition of the risk in patients affected by TR and left heart valve dis-
ease undergoing percutaneous procedures. Secondly, a more defined
approach to the quantification of the severity of the TR is needed.
Currently, in clinical practice, the quantification of TR is less standar-
dized than it is for mitral valve. The same semi quantitative and quan-
titative methods used for mitral valve should be systematically
employed to quantify TR.
Thirdly, does TR improve as a result of the correction of the left
heart valve disease or is it necessary a combined approach involving
tricuspid valve? After the correction of the left heart valve disease
there is an improvement of the TR,9,12 even if this phenomenon
seems to be extremely variable13 and related also to other comor-
bidities and heart disease. Thus, new tailored randomized trials are
needed to determine whether the presence of moderate to severe
TR, with or without right ventricular or annular dilatation, is a new
potential target for a combined percutaneous approach in patients
undergoing percutaneous left heart valve procedure. This could be
particularly important since several and new percutaneous tech-
niques are now available to treat also tricuspid valve. The cardioband
device (ValtechCardio, OrYehuda, Israel) is an already successfully
used transcatheter annuloplasty system consisting in a Dacron band
implantable under echocardiographic and fluoroscopic guidance;24
the Trialign is another sutarable annuloplasty system device, which is
under evaluation in the Early Feasibility of the Mitralign Percutaneous
Tricuspid Valve Annuloplasty System (PTVAS) Also Known as
Trialign (SCOUT) (NCT02574650) trial;25 mitraclip system has al-
ready been used to successfully treat patients with TR26 and finally
also The TriCinch (4Tech Inc., Galway, Ireland) device is another po-
tential option for the percutaneous treatment of TR.27
All these unsolved issues suggest that a ‘mentality shift’ in the per-
cutaneous approach to heart valve is needed. Nowadays, the use of
echocardiography is crucial to guide the selection of the patients and
correct apposition of the mitraclip.28 As for TAVI, the whole proced-
ure is planned on a combined approach made by echocardiography,
multislice computed tomography, angiography, and cardiovascular
magnetic resonance.29 Along with this ‘procedure-centred’ approach,
a more detailed and shared evaluation of the tricuspid valve disease
severity would be necessary to understand its impact and the pos-
sible need of a standardized combined approach involving also the
treatment of tricuspid valve in patients undergoing TAVI or mitraclip.
Study limitation
This is a study level meta-analysis and for this reason it has several
limitations. First of all, we compared data of patients treated for mi-
tral regurgitation with those treated for aortic stenosis. However,
subgroup analysis confirmed the same data also for every single cat-
egory of patients. Secondly, factors analysed at the multivariate ana-
lysis are widely different among studies and in particular we
considered data at the univariate analysis for the study of Hutter et al.
Figure 3 Funnel plot and trim and fill analysis for publication bias detection.


























































































..Nevertheless, heterogeneity expressed as I2 was insignificant.
Moreover, including only data from univariate analysis from the stud-
ies of Ohno, Barbanti, Hutter, and Lindman the cumulative HR of se-
vere TR for all-cause death was 2.61 (95% CI 1.73–3.96, I2 = 52%)
(Supplementary data online, eFigure S3), showing a higher degree of
heterogeneity, but the same increased HR for all-cause death.
Thirdly, only one study showed data about cardiovascular death.
Finally, there are no data to clearly define the pathophysiologic mech-
anism behind the TR (e.g. annular dilatation, right ventricle dysfunc-
tion, and degenerative disease) and how other factors like systolic
PAP or EF change in the follow-up. For all these limitations and be-
cause this meta-analysis is based on data coming from observational
study and one RCT, data obtained should be considered only hypoth-
esis generating and a background to plan future trial to define the cri-
teria for the percutaneous treatment of TR in patients with
concomitant left heart valve disease undergoing TAVI or mitraclip.
Conclusions
The current meta-analysis suggests that the presence of moderate to
severe TR in patients undergoing mitraclip or TAVI might be a major
determinant of all-cause mortality. New studies are needed to con-
firm it and to plan possible intervention in order to reduce its impact.
Supplementary data
Supplementary data are available at European Heart Journal—
Cardiovascular Imaging online.
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